Vast Majority of Contralateral Prophylactic Mastectomies Unnecessary

by U.S. Medicine

June 18, 2013

By Sandra Basu

Sarah Hawley, PhD

ANN ARBOR, MI — Are healthcare providers doing enough to educate and advise breast cancer patients on their options, thereby avoiding unnecessary contralateral prophylactic mastectomy?

New research raises questions about the process leading to often unnecessary surgery.

A study led by Sarah Hawley, PhD, a research investigator at the Ann Arbor VA Center of Excellence in Clinical Care Management Research, noted that about 70% of women who have both breasts removed following a breast cancer diagnosis do so even though they face a very low risk of cancer in the healthy breast. The findings were presented at the American Society of Clinical Oncology’s Quality Care Symposium in November 2012.1

“There seems to be some knowledge gaps related to the procedure options that women choose between, and there also seems to be this real fear of breast cancer coming back that seems to be pervasive, regardless of the kinds of treatments that women get and regardless of the likelihood of their cancer coming back,” Hawley, who is also associate professor of internal medicine at the University of Michigan Medical School, told U.S. Medicine.

Contralateral prophylactic mastectomies generally are not recommended for consideration unless there is a family history of multiple members with breast or ovarian cancer or the patient has a positive genetic test for mutations in the BRCA1 or BRCA2 genes. In fact, one 2010 study published in the Journal of the National Cancer Institute suggested that CPM offered a small improvement in five-year breast cancer-specific survival only in young women with early-stage ER-negative breast cancer.

Despite that, research indicates that the procedure has not waned in popularity. A 2010 study published in the Annals of Surgical Oncology found that patients choosing preventive removal of the unaffected breast grew from 0.4% in 1998, to 4.7% in 2007. 2

Breast Cancer

Hawley said that, for the study, she and her co-authors looked at 1,446 women who had been treated for breast cancer and who had not had a recurrence. They found that 7% of women had surgery to remove both breasts. Nearly 1 in 5 had a double mastectomy among the women who had a mastectomy.

“We had a sample of 1,450 women who were in this analysis and of those 110 had a double mastectomy. When we looked at the group that got double mastectomy, 30% of them had a clinical indication, which we defined as having a genetic mutation and/or having a very strong family history, which would be two or more first degree relatives with breast or ovarian cancer,” Hawley pointed out. “The other 70% didn’t have either of those factors.”

As part of the study, researchers asked the women how much worry about cancer recurrence figured in their decision process. The study found that 90% of women who had surgery to remove both breasts reported being very worried about the cancer recurring.

Hawley noted that, except for those who have a genetic mutation or strong family history, removing the second breast likely is of little benefit.

Breast cancer found in one breast after biopsy (shown above) does not usually require prophylactic mastectomy of the other breast. Photo from the National Cancer Institute, Photographer: Linda Bartlett
Breast Cancer Con’t

“It is really not helping them in terms of their survival of this disease to get their breast removed. One would expect that would not be recommended, because that is yet another surgery with the potential for complications and recovery time that you wouldn’t want to embark on if you didn’t need it,” she said.

Hawley said the “million-dollar question” is what kind of discussion occurred between clinicians and the 70% of patients who chose a double mastectomy without a clinical indication. She suggests, however, that it is highly unlikely that a double mastectomy was recommended by their physician.

Clinical Diagnosis of BRCA 1 and BRCA2 Mutations
If one or more of the following features are present in a family, hereditary breast and ovarian cancer (HBOC) resulting from germ line mutations in BRCA1 and BRCA2 is suspected and further risk evaluation is warranted.
  • Early-age-onset (age <50 years) breast cancer including both invasive and ductal carcinoma in situ (DCIS) breast cancers
  • Two breast primaries or breast and ovarian/fallopian tube/primary peritoneal cancer in a single individual or two or more breast primaries or breast and ovarian/fallopian tube/primary peritoneal cancers in close (first- second- and third-degree) relatives(s) from the same side of the family
  • Populations at risk (e.g., Ashkenazi Jewish)
  • Member of a family with a known BRCA1 or BRCA2 mutation
  • Any male breast cancer
  • Ovarian/fallopian tube/primary peritoneal cancer at any age
Source: National Comprehensive Cancer Network

“It is probably something that women ask about who have this very strong worry that they just want to do everything possible to get it out, including something that might not be necessary to have done,” she said.

She said that among the questions the researchers are exploring is what role the desire for breast reconstruction may have played in patients’ decisions to get a double mastectomy.

“A lot of times it is suggested that it is easier to reconstruct two breasts to be cosmetically similar than one, and so if you are seeing that plastic surgeon as part of your discussion and they mention this, then you may embark on double mastectomy for cosmetic reasons. We weren’t able to look at that yet in our data, but we are able to look at it in some follow-up analysis that we are doing,” she said.

Hawley and her colleagues received a grant from the National Cancer Institute that is helping them develop a decision tool to help guide women through breast cancer treatment choices. This tool will entail an interactive website that will help women go through the key information they need to make decisions about treatment such as double mastectomies.

“If it works the way that we want it to, then some women who come in and are thinking of getting double mastectomy or unilateral mastectomy, they may end up realizing that they could go with something less and still have the same survival benefits,” she said.

Women’s Health

VA patient data was not included in Hawley’s research, but Chief of Plastic Surgery at the Bay Pines VA Healthcare System Wyatt Payne, MD, told U.S. Medicine that education is key in helping women, both in the VA and outside of VA, make a decision regarding prophylactic mastectomies.

“One of the best things that physicians, nurses and other providers can do is to try to help allay unfounded fear and to educate our patients as to what the real facts are and to try to help them understand the situation,” he said.

Payne pointed out that, unless a patient is in a high-risk group, the risk of developing breast cancer in the other breast is relatively low. In the VA, like elsewhere, Payne said contralateral prophylactic mastectomies generally would be recommended for consideration only when there is a strong clinical indication.

According to VA, since 2000 the number of female veterans using VA healthcare more than doubled, from nearly 160,000 to more than 337,000 in fiscal year 2011. The agency said in a press release last year that it has outperformed non-VA healthcare systems in breast cancer screenings for more than 15 years, with 87% of eligible women receiving mammograms in the VA healthcare system in fiscal year 2010.

1. Hawley ST, Jagsi R, Katz SJ. Is Contralateral Prophylactic Mastectomy (CPM) Overused? Results from a Population-Based Study, American Society of Clinical Oncology Quality Care Symposium, San Diego, Nov. 30-Dec. 1, 2012.

2. Yao K, Stewart AK, Winchester DJ, et al: Trends in Contralateral Prophylactic Mastectomy for Unilateral Cancer: A Report from the National Cancer Data Base, 1998-2007. Ann Surg. Oncol 17:2554-2562, 2010.

Comments are closed here.

Related Articles

Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

Veterans Study Calls for Better Guidance on Lung Cancer Treatment

With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.

U.S. Medicine Recommends

More From department of defense dod

Department of Defense (DoD)

DoD acknowledges its medical adverse event reporting is ‘unreliable’

The process for tracking the DoD’s most serious adverse medical events is “fragmented, impeding the Defense Health Agency’s (DHA) ability to ensure that it has received complete information,” according to a new review.

Department of Defense (DoD)

Automation Speeds Results and Increases Accuracy for Point-of-Care Testing at Walter Reed NMMC

With a long history of point of care testing at both of its predecessor organizations, the Walter Reed National Military Medical Center (WRNMMC) laboratory services staff were keenly aware of the advantages of using portable testing devices to obtain rapid patient assessments.

Department of Defense (DoD)

High Rate of Pectoralis Tears Among Deployed Servicemembers Lifting Weights

Lifting weights is one way servicemembers keep in peak physical condition during deployment.

Department of Defense (DoD)

DoD Study Finds That Type 2 Diabetes Increases Breast Cancer Mortality

Having Type 2 diabetes mellitus (DM-2) increases mortality risk in breast cancer patients, regardless of whether diabetes was diagnosed before or after breast cancer, according to a recent study.

Department of Defense (DoD)

Now Hear This: Otolaryngologist Leads Effort to Prevent Auditory Issues

Among those who are exposed to combat, it’s the weapons fire that does it. In the Navy, it’s the noise levels in engine rooms and on the decks of carriers.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up